Ophthalmology

Peter Kaiser, MD, presented data from a phase 2 trial examining the safety and efficacy of risuteganib at ASRS 2019.

W. Lloyd Clark, MD, discusses the approaches he uses in his clinical practice to reduce patient noncompliance — specifically, when treating diabetic macular edema.

As physician burnout becomes a more common issue, physician across an array of fields find themselves discussing and formulating ways to circumvent burnout.

Physician from Palmetto Retina Center on deciding between aflibercept, ranibizumab, and avastin for treatment of DME.

Here's a primer for new data and discussions MD Mag will be covering this weekend in Chicago.

Kodiak's KSI-301 was shown to have sustained benefit and safety in a phase 1a study involving patients with severe DME.

Several new generics available to treat neuropathic pain linked to diabetic peripheral neuropathy, fibromyalgia partial onset seizures, and other conditions.

Analysis of 2 phase 3 trials found that 24% of patients experienced new choroidal neovascularization over the course of the 96-week trials.

An analysis of more than 650 eyes find that optical coherence tomography central subfield thickness accounts for only a small proportion of total variation in changes in visual acuity.

Investigators examined anti-VEGF injections claims data among Medicare Part B beneficiaries from 2012 to 2015 and found that aflibercept injections increased by 69% during that time.

A recent study reviewed operating times of ophthalmic procedures before and after transition to a new EHR system in 2 outpatient departments and an ambulatory surgical center.

Patients who received the implant in addition to the surgery showed more positive results than the control group in a randomized, single-masked study.

Ranibizumab was approved for AMD treatment in Korea in 2007, but most supporting trials had been conducted among Caucasian patients.

A review highlights aflibercept’s efficacy in treatment non-responders and points to a couple promising new AMD therapies in development.

Self-reported vision impairment was associated with a greater risk of developing depression and anxiety symptoms in patients 65 and older.

Metformin use associated with a 58% reduced risk of age-related macular degeneration (AMD) in a case-controlled retrospective study.

Aflibercept (Eylea) is an anti-VEGF treatment administered as an intravitreal injection.

The FDA has expanded the indication for incobotulinumtoxinA (Xeomin) to include treating blepharospasm (involuntary blinking) in adults.

Investigators found that female sex, older age, and certain comorbidities were associated with an increased risk of uveitis.

Using a national medical claims database, investigators found the incidence and prevalence of uveitis in the US.

Results from the 3-year European Iluvien Registry Safety Study that examined outcomes of the fluocinolone acetonide implant compared to those of the pivotal FAME trials.

After analyzing more than 3700 systematic reviews, investigators found that 1 in 3 were unreliable.

Investigators calculated perilesional sensitivity and responding sensitivity for eyes in a geographic atrophy clinical trial and compared these to mean retinal sensitivity.

Chang and colleagues are developing an outcome for geographic atrophy trials that measures vision loss rather than structural changes.

Patients who experienced hypertensive disorders in pregnancy were 80% more likely to develop choroidal neovascular AMD at an early age.

An early-start treat-and-extend regimen produced comparable efficacy with fewer aflibercept injections than regular injections every 8 weeks.

A study presented at ARVO 2019 examines the long-term safety of BAK-free latanoprost for treatment of open-angle glaucoma or ocular hypertension

A recent study, presented at ARVO 2019, found that ophthalmologists have 77% greater odds of experiencing professional fulfillment, but ophthalmology residents are 3 times more likely to express an intent to leave the field than other surgical residents.

A study from ARVO 2019 found that, while optometrists are likely to prescribe them, many are still split over the impact of blue light-blocking devices

A tear-based biomarker for Parkinson disease would allow providers to diagnose the condition sooner and create a measurement tool for new drug development.